KHONDRION

KHONDRION is a clinical-stage pharmaceutical company focused on discovering and developing therapies targeting mitochondrial disease. Founded by a world-leader in mitochondrial medicine, KHONDRION is dedicated to advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. The company’s priority is to rapidly develop its pipeline to deliver transformative medicines for patients living with mitochondrial disease. The Primary address of KHONDRION is Philips van Leydenlaan 15, Nijmegen, PO BOX 9101, 6525 EX, NL.

KHONDRION's in-house scientists are driving innovative research projects and building a portfolio of promising compounds. With active discovery programs underway, KHONDRION is developing new therapies, biomarkers, diagnostic applications, and new read-out technologies in the field of mitochondrial diseases. KHONDRION's lead pipeline asset, sonlicromanol, is a potential Phase 3 ready first-in-class oral small molecule in clinical development to treat a range of primary mitochondrial diseases. It has been granted Orphan Drug Designation for all inherited mitochondrial respiratory chain/oxidative phosphorylation disorders in the US and EU.

KHONDRION works in collaboration with patient organizations internationally, as well as a global clinical and academic network, to accelerate the discovery and development of potential medicines for patients with mitochondrial diseases. We invite the manager of KHONDRION to create a customized and exclusive company showcase and product listing on our platform.